Healthcare Services

A key trend shaping the Meibomian Gland Dysfunction Market involves the Innovative Eye Drop Therapies Target Root Causes Of Tear Evaporation And Dry Eye Symptoms

April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Meibomian Gland Dysfunction Market By 2030 Starting From Its 2026 Size?

The meibomian gland dysfunction market size has experienced significant expansion in recent years. It is anticipated to grow from $4.42 billion in 2025 to $4.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. The increase observed in the historic period is attributable to the increasing incidence of dry eye disease, higher screen time exposure, aging population growth, wider clinical recognition of mgd, and the availability of basic treatment options.

The meibomian gland dysfunction market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $6.12 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This projected growth during the forecast period is fueled by factors such as the greater acceptance of device-assisted therapies, increased investments within ophthalmic care, heightened awareness regarding chronic eye conditions, the wider availability of home-use treatment devices, and an intensified emphasis on personalized eye care. Key trends expected throughout the forecast period encompass a surge in the adoption of advanced diagnostic instruments, an uptick in the utilization of device-based therapies, an evolving preference for combined treatment methods, the proliferation of home-based management solutions, and a stronger emphasis on identifying diseases early.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24602&type=smp

Which Market Drivers Are Supporting The Expansion Of The Meibomian Gland Dysfunction Market?

The increasing incidence of eye disease is anticipated to drive the expansion of the meibomian gland dysfunction (MGD) market in the future. Eye disease refers to any ailment or condition affecting the eye or visual system, impairing its structure, function, or overall health. The rising cases of eye disease are attributed to increased screen time and digital eye strain, which manifest as symptoms such as dryness, blurred vision, and long-term retinal damage from prolonged exposure to blue light. Meibomian gland dysfunction contributes to eye disease by disrupting the stability of the tear film, leading to inflammation, dryness, and an elevated risk of ocular surface disorders. For instance, in February 2025, the National Institutes of Health (NIH), a US-based government agency, indicated that the global prevalence of myopia is expected to climb to 36.59% by 2040 and 39.80% by 2050, with the total number of cases estimated to exceed 740 million by 2050. Therefore, the growing number of eye disease cases is fueling the growth of the meibomian gland dysfunction (MGD) market.

Which Segment Categories Define The Meibomian Gland Dysfunction Market?

The meibomian gland dysfunction market covered in this report is segmented –

1) By Treatment Type: Medication, Surgery, Lifestyle Modifications

2) By Dysfunction Type: Obstructive Meibomian Gland Dysfunction, Evaporative Meibomian Gland Dysfunction, Mixed Meibomian Gland Dysfunction

3) By Disease Severity: Mild Meibomian Gland Dysfunction, Moderate Meibomian Gland Dysfunction, Severe Meibomian Gland Dysfunction

4) By Distribution channel: Hospitals And Clinics, Pharmacies, Online Retailers

5) By End-User: Hospitals, Ophthalmology Clinics, Home Care Settings

Subsegments:

1) By Medication: Topical Antibiotics, Topical Steroids, Lubricating Eye Drops, Topical Cyclosporine, Omega-3 Supplements

2) By Surgery: Meibomian Gland Probing, Intense Pulsed Light (IPL) Therapy, Thermal Pulsation Treatment, BlephEx

3) By Lifestyle Modifications: Warm Compress Therapy, Lid Hygiene, Dietary Adjustments, Blinking Exercises

What Industry Trends Are Redefining The Meibomian Gland Dysfunction Market?

Leading companies within the meibomian gland dysfunction market are prioritizing the creation of innovative treatments, such as prescription eye drop solutions, aimed at reducing tear evaporation and alleviating dry eye symptoms. These prescription eye drop solutions, which can include anti-inflammatory or antibiotic varieties, contribute to managing meibomian gland dysfunction by decreasing inflammation, clearing gland obstructions, and enhancing tear film stability. For example, in May 2023, Bausch + Lomb Corporation, a Canada-based eye health company, launched MIEBO (perfluorohexyloctane ophthalmic solution), an innovative prescription eye drop developed for the treatment of dry eye disease (DED). As the inaugural and only prescription eye drop specifically designed to tackle tear evaporation, the primary cause of DED, MIEBO establishes a lasting, protective film over the eye’s surface. Its advanced water-free formulation delivers effective and enduring relief, particularly for patients whose dry eye symptoms are linked to Meibomian gland dysfunction.

Who Are The Top Companies Competing In The Meibomian Gland Dysfunction Market?

Major companies operating in the meibomian gland dysfunction market are Johnson And Johnson, Alcon Inc., Bausch Lomb Corporation, Santen Pharmaceutical, Lumenis Ltd, Topcon Healthcare Solutions Inc, AFT Pharmaceuticals, Sight Sciences Inc, OASIS Medical Inc, OCuSOFT Inc, Novaliq GmbH, Scope Ophthalmics Ltd, Medmont International Pty Ltd, Azura Ophthalmics Ltd, BlephEx LLC, Bruder Healthcare Company, ESW Vision Inc, MiBo Medical Group Inc, Kala Pharmaceuticals Inc, Allergan Eye Care, TearScience Inc, Sun Pharmaceutical Industries Ltd

Read the full meibomian gland dysfunction market report here:

https://www.thebusinessresearchcompany.com/report/meibomian-gland-dysfunction-global-market-report

How Is The Meibomian Gland Dysfunction Market Distributed Across Key Geographic Regions?

North America was the largest region in the meibomian gland dysfunction market in 2025. The regions covered in the meibomian gland dysfunction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Meibomian Gland Dysfunction Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24602&type=smp

Browse Through More Reports Similar to the Global Meibomian Gland Dysfunction Market 2026, By The Business Research Company

Cardiovascular Monitoring And Diagnostic Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/cardiovascular-monitoring-and-diagnostic-devices-and-equipment-global-market-report

Congestive Heart Failure Treatment Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-treatment-devices-global-market-report

Anti Hypertensive Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795